Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Health care delivery in general and nephrology in particular are being impacted by new health information technology (HIT). Patients using personal devices for monitoring sleep, physical activity, diet, and vital signs are more engaged in their care. The dialysis treatment itself is more automated with multiple technological machine advancements. Data collected by dialysis machines is now stored in organized repositories and is available in real time for centralized interventions. This ability to collect real-time data from multiple sources has been termed pervasive sensing or the “Internet of things,” a development of the Internet in which everyday objects have network connectivity and ability to transfer data.
Mathematical and data sciences have been advancing alongside technology. Predictive modeling has become a topic of everyday conversation—from detailed and reliable weather forecasts to predicting our shopping choices on Amazon. Machine learning and artificial intelligence are also gaining presence in our lives. Computers can recognize diabetic retinopathy as effectively as clinicians do.5
These technological advancements can help us get a 360-degree view of our patients, something that traditionally required extremely intimate knowledge of the patient. This panoramic view of the patient may indeed allow us to move from what has become standardized care to highly personalized care.
Another concurrent development that can assist in further personalizing care is genetic research. Since the building block of genetics, deoxyribonucleic acid (DNA), was first isolated in 1869 by Friedrich Miescher and its molecular structure identified in 1953, scientists have hoped to utilize genetic information to customize therapy.
The Human Genome Project, completed in 2003, resulted in sequencing the entire human genome and in identifying and mapping all the genes of the human genome from both a physical and a functional standpoint.6
In 2015, President Obama launched the “Precision Medicine Initiative.” Precision medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”7 Although the term is relatively new, the concept has been around for decades. For example, a person who needs a blood transfusion is not given blood from a randomly selected donor; instead, the donor’s blood type is matched to the recipient.
A rapidly increasing number of studies proclaim the hopes of precision medicine and government initiatives to support such efforts. Precision medicine has been accepted as an important consideration in oncology, but it has also been applied in cardiology and is finding a home in nephrology.8 In fact, literature suggests that “the nephrology research community has developed a strong foundation for precision medicine.”9
In nephrology, much of the application of genetic testing has been about understanding factors that predict the development and progression of CKD. Discovery of APOL1 gene in people with African ancestry has been instrumental in understanding disease progression in African Americans. Not only the United States, but also other countries are realizing the importance of genetic testing. Fifteen years ago, the European Renal cDNA Bank was organized to advance precision medicine.10
Pharmacogenetics uses genetic information to explain drug hyper- and hypo-responses. Inherited variations in approximately 20 genes affect about 80 medications, most of which can be actionable in the clinic.11
More than 1,200 molecular testing entities are approved for use in the United States, Europe, and Asia.12 This proliferation of testing labs will drive down the cost of genetic testing. Today, some payors don’t cover the cost of genetic testing, but this will likely change as the value of gene testing is proven. Multiple public databases are available for genetic testing research and are being routinely updated, such as PharmGKB, ClinGen, and ClinVar.
Caregivers should think more holistically than just genetically driven precision nephrology. Personalized nephrology is a care delivery paradigm where care is delivered to the right patient, at the right time, and with the right treatment based on today’s clinical condition and a patient’s unique cellular and physiologic makeup. Personalized nephrology relies on sophisticated and integrated technology solutions—a panoramic view of the patient is essential to such care delivery. Research has shown that the development of large-scale biologic databases, powerful methods for characterizing patients, and computational tools for analyzing large amounts of data result in clear benefits.13
In 2011, a US National Academy of Sciences report used the analogy of Google Maps to illustrate the value and necessity of integrating diverse data sets into a comprehensive knowledge network (Figure 1).
Having an integrated technology solution is not enough. Robust tools will be needed to assist clinicians in identifying specific and actionable steps to take based on the exact background of the patient, with his or her own genetic variation and outcomes predicted by data analysis.
Fresenius Medical Care is utilizing specific components of personalized nephrology. As an organization, we have 12 predictive models that provide personalized results to identify patients at a higher risk of hospital admissions, higher likelihood of missing a treatment, higher risk of mortality, or higher risk of progressing to ESRD. We also have multiple personalized algorithms that compute ESA doses per treatment or combine numerous variables into a functional status index.
Many of these models have proven to be successful in pilot and clinical settings. For example, the Dialysis Hospitalization Reduction (DHR) pilot was associated with a 10 percentage point reduction in hospital days over a 12-month period in participating clinics compared to non-DHR clinics in the organization.
Chronic disease management provides a good opportunity for implementing personalized holistic patient care. Typically, chronically ill patients will have multiple providers, and no one care provider has the panoramic view of the entire problem. We only “touch” some of the aspects of the disease, like the “blind men touching various parts of the elephant trying to identify what it really is.”14
Personalized nephrology care and treatment provides an interesting example of transitioning from highly individualized treatment in 1962 to improvement in outcomes in recent years from standardization of care. In the near future, Fresenius Medical Care will have the opportunity to deliver personalized, precise care delivered to the right patient at the right time in the context of an organized, standardize system. This opportunity for precision medicine delivery in nephrology is made possible by general HIT advancements that promote continuous monitoring and patient engagement; sophisticated real-time data management that customizes care delivery; and advanced analytics on large data sets that support personalized treatment decisions.
Analogy of Multi-Layer Google Maps and Understanding of Patient Information through “Patient Commons”
The proposed individual-centric Information Commons (right panel) is somewhat analogous to a layered Geographical Information System (left panel). In both cases, the bottom layer defines the organization of all the overlays; however, in a GIS, any vertical line through the layers connects related snippets of information since all the layers are organized by geographical position. In contract, data in each of the higher layers of the Information Commons will overlay on the patient layer in complex ways (e.g. patients with similar microbiomes and symptoms may have very different genome sequences). Source: FPA 2011 (left panel)
Len Usvyat, PhD
Vice President of Integrated Care Analytics
Fresenius Medical Care North America
Dr. Len Usvyat chairs Fresenius Medical Care North America’s Predictive Analytics Steering Committee and works closely with the MONitoring Dialysis Outcomes (MONDO) initiative, an international consortium of dialysis providers. His team provides analytical support for the company’s pharmacy, vascular care centers, urgent care facilities, hospitalist group, health plan and Medical Office research. He graduated with his PhD from the University of Maastricht in the Netherlands.
by Len Usvyat, PhD